Yongluan Lin

Dr. Yongluan Lin


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HLHailin Liang
Hailin Liang
CZChujuan Zeng
Chujuan Zeng
JHJunhong Huang
Junhong Huang
YLYongluan Lin
Yongluan Lin
SCSongming Chen
Songming Chen
Stress hyperglycemia ratio (SHR) has been associated with adverse clinical outcomes in hospitalized patients with acute coronary syndromes (ACS). However,

8 July 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
JLJiacai Lin
Jiacai Lin
SQShaobin Qiu
Shaobin Qiu
SSShuling Su
Shuling Su
WNWeixin Ni
Weixin Ni
YLYongluan Lin
Yongluan Lin
XNXiaobin Ni
Xiaobin Ni
Background: Patients with cardiovascular-kidney-metabolic (CKM) syndrome have high mortality risk. The C-reactive protein–triglyceride glucose index (CTI) integrates inflammation and insulin resistance, yet its stage-specific prognostic value is undefined. Methods and results: This retrospective cohort study included 8,632 CKM patients (2020–2025), stratified by CTI quartiles. All-cause mortality was assessed using adjusted Cox models. Among 860 deaths (10.0%), CTI was an independent mortality predictor in both stage 0–3 (HR 1.68, 95% CI 1.30–2.18) and stage 4 CKM (HR 1.54, 1.33–1.77). Compared with Q1, Q4 patients had significantly higher risk (stage 0–3: HR 4.57, 2.32–8.99; stage 4: HR 2.26, 1.64–3.13). A linear dose-response relationship was confirmed ( P for nonlinear >0.05). CTI showed superior 1-year predictive performance over TyG index (AUC: stage 0–3, 0.73 vs. 0.62; stage 4, 0.69 vs. 0.51). Conclusion: CTI is a potent, independent predictor of all-cause mortality in CKM, with a linear dose-response relationship. By integrating inflammatory and metabolic pathways, it provides superior risk stratification over TyG index, highlighting its clinical utility.

22 September 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
JHJunhong Huang
Junhong Huang
YWYanping Wang
Yanping Wang
HLHailin Liang
Hailin Liang
HTHaoxian Tang
Haoxian Tang
XDXiulian Deng
Xiulian Deng
YCYequn Chen
Yequn Chen
Given the frequent coexistence and bidirectional relationship of atrial fibrillation (AF) and chronic kidney disease (CKD), and the known cardiovascular ri